PARP1 and soft tissue sarcoma: On the basis of these and other clinical evidence, which showed encouraging activity of the PARP inhibitor olaparib in bone and soft-tissue sarcomas [30], targeting PARP appears to be a promising therapeutic strategy to be further explored.